Phase IIT Trial of SNA014

SmartNuclide Biopharma

Status and phase

Not yet enrolling

Early Phase 1

Conditions

Adenocarcinoma of the Stomach

Adenocarcinoma of GE Junction

Pancreatic Cancer Stage

Treatments

Drug: [68Ga]Ga-NODAGA-SNA014

Study type

Interventional

Funder types

Industry

Identifiers

[68Ga]Ga-NODAGA-SNA014

Details and patient eligibility

About

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction

Enrollment

28 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age range of 18 to 75 years old (including boundary values);
Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (ICF);
Diagnosed G/GEJ adenocarcinoma and pancreatic cancer;
Gastroscopy/CT/MRI/PET-CT examination results within the past month (if any);
Pathological test results and Claudin18.2 immunohistochemistry results within the past year (if available).

Exclusion criteria

Merge patients with other clearly diagnosed malignant tumors:
Uncontrolled severe infections or individuals with other serious illnesses;
Those with an expected survival period of less than or equal to three months;
Pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate contraceptive measures during this trial;
investigators determine that patients who are not suitable to participate in this study;